Navigation Links
Chemo for Late-Stage Cancer Patients May Be Unjustified
Date:6/9/2011

THURSDAY, June 9 (HealthDay News) -- Some patients with advanced cancer receive drugs that won't help them but could cause them harm, a U.S. study suggests.

University of Chicago researchers analyzed medical and pharmaceutical claims from 1,041 patients with metastatic colon cancer who were treated between January 2007 and June 2010. Of those patients, about one in eight received chemotherapy treatments that weren't supported by evidence from clinical trials or by clinical practice guidelines.

The researchers focused on three specific treatments. One had insufficient data to support its use, one had been shown to be ineffective, and one was not supported by data or a compelling rationale, according to the study.

The treatment with insufficient data involved the use of Avastin (bevacizumab) after a patient's cancer had progressed despite treatment with a combination of the drug and chemotherapy. The treatment shown to be ineffective was Xeloda (capecitabine) after cancer progression while being treated with the same class of drug. The treatment with no compelling rationale was Erbitux (panitumumab/cetuximab) after cancer progression while being treated with similar drugs.

The researchers said the patients who received these treatments were exposed to significant risk without proven benefits at an estimated cost of more than $2 million just for the drugs.

"Patients with advanced cancers that do no respond to standard therapies should either be looking for clinical trials, where there is a chance for benefit, or should have been thinking about shifting toward palliative care," study author Dr. Jonas De Souza, a hematology/oncology fellow, said in a university news release.

"Patients should not face the risks, discomforts and costs of aggressive and often quite toxic chemotherapy with treatment regimens that did not provide a benefit in previous studies," he added.

The study was presented this week at the American Society for Clinical Oncology's annual meeting in Chicago. Experts note that research presented at meetings should be considered preliminary because it has not been subjected to the rigorous scrutiny given to research published in medical journals.

More information

The U.S. National Cancer Institute has more about metastatic cancer.

-- Robert Preidt

SOURCE: University of Chicago, news release, June 6, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Tai chi could be key to overcoming cognitive effects of chemotherapy
2. Hormone test predicts ovarian function after chemotherapy for breast cancer
3. Taking Chemo Drug Continuously Delayed Lung Cancers Return
4. After Colon Cancer Surgery, Early Chemo May Pay Off
5. Following colorectal cancer surgery, longer delay before chemotherapy associated with worse survival
6. Antifungal drug delays need for chemo in advanced prostate cancer
7. Many patients fail to properly take oral chemo, leading to complications
8. Gene-modified stem cells help protect bone marrow from toxic side effects of chemotherapy
9. Chemo Combo May Help Stave Off Pancreatic Cancer Death
10. Genetic information may help predict likelihood of survival following chemotherapy for breast cancer
11. Genomic test shows promise as chemotherapy response, survival predictor for women with breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Chemo for Late-Stage Cancer Patients May Be Unjustified
(Date:9/22/2017)... ... September 22, 2017 , ... SABRE ... Scholarship Sweepstakes.,  , Molli C., a graduate student from Sonora, California, who will ... Administration at St. Thomas University in Miami, Florida, was selected from a pool ...
(Date:9/22/2017)... HOUSTON, Texas (PRWEB) , ... September 22, 2017 ... ... leading network of independent freestanding emergency rooms is celebrating the one year anniversary ... anniversary of our facility opening,” said Dr. Otinwa, Facility Medical Director of First ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... products at customers’ doorstep. According to Smart Mart, customers can now order vegetable, ... offer wearable, and customers can find clothing at discounted prices. Apart from this, ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability ... p.m. – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality ... run afoul of The Quality System Regulation (§820.250), and Devicemakers find themselves staring ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... in their communities, nine governmental public health departments have been awarded five-year accreditation ... decisions mean that the benefits of being served by a PHAB-accredited health ...
Breaking Medicine News(10 mins):
(Date:9/13/2017)... Sept. 13, 2017   OrthoAtlanta has been named ... Football Host Committee (AFHC) for the 2018 College Football Playoff ... 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... AFHC "I,m In" campaign, participating in many activities leading up ... ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., ... Solutions (VLMS), is pleased to announce the appointment ... member of its Board of Directors and Chairman ... VLMS enables life science companies to manage their ... use of paper in this process. Furthermore, ValGenesis ...
(Date:9/9/2017)...  Eli Lilly and Company (NYSE: LLY ... for lasmiditan, an investigational, oral, first-in-class molecule for the ... compared to placebo in the Phase 3 SPARTAN study. ... Congress of the International Headache Society (IHC) in ... today demonstrate lasmiditan,s potential to reduce pain and provide ...
Breaking Medicine Technology: